Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | CIT | O14578 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20863906 | 0.86 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2SPHK1MAPT | |
| SCHEMBL20864026 | 0.86 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2SPHK1MAPT | |
| SCHEMBL12243459 | 0.86 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2SPHK1MAPT | |
| SCHEMBL16401886 | 0.86 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2SPHK1MAPT | |
| SCHEMBL20733347 | 0.86 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2SPHK1MAPT | |
| SCHEMBL19358962 | 0.86 | SMN1; SMN2 (0.44) | NPC1RAB9ASMN1; SMN2SPHK1MAPT | |
| SCHEMBL22283234 | 0.86 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2SPHK1MAPT | |
| SCHEMBL24101234 | 0.84 | SMN1; SMN2 (0.40) | NPC1RAB9ASMN1; SMN2SPHK1MAPT | |
| SCHEMBL25993246 | 0.84 | SMN1; SMN2 (0.40) | NPC1RAB9ASMN1; SMN2SPHK1MAPT | |
| SCHEMBL30634406 | 0.83 | LSS (0.43) | NPC1RAB9ASMN1; SMN2SPHK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233703-A1 | AMANITIN CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233703-A1 | AMANITIN CONJUGATES | CD47, MTX1, SIGLEC7 | NPC1 3747/4885RAB9A 1706/4885SMN1; SMN2 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.